Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (22)

2024

  1. Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates

    Gut

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2022

  1. Detailed stratified GWAS analysis for severe COVID-19 in four European populations

    Human Molecular Genetics, Vol. 31, Núm. 23, pp. 3945-3966

  2. Genetic Inactivation of Free Fatty Acid Receptor 3 Impedes Behavioral Deficits and Pathological Hallmarks in the APPswe Alzheimer’s Disease Mouse Model

    International Journal of Molecular Sciences, Vol. 23, Núm. 7

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

2020

  1. Reversal of Object Recognition Memory Deficit in Perirhinal Cortex-Lesioned Rats and Primates and in Rodent Models of Aging and Alzheimer's Diseases

    Neuroscience, Vol. 448, pp. 287-298

  2. Smelling the Dark Proteome: Functional Characterization of PITH Domain-Containing Protein 1 (C1orf128) in Olfactory Metabolism

    Journal of Proteome Research, Vol. 19, Núm. 12, pp. 4826-4843

2019

  1. Dopamine receptor D3 expression is altered in CD4+ T-cells from Parkinson's disease patients and its pharmacologic inhibition attenuates the motor impairment in a mouse model

    Frontiers in Immunology, Vol. 10, Núm. MAY

2018

  1. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

    Biochemical Pharmacology, Vol. 157, pp. 67-84

  2. Maternal imprinting on cognition markers of wild type and transgenic Alzheimer's disease model mice

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease

    Neuropharmacology, Vol. 113, pp. 110-123

2016

  1. Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys

    Biomaterials, Vol. 110, pp. 11-23

  2. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson's disease

    Brain, Behavior, and Immunity, Vol. 57, pp. 94-105

  3. Limited unfolded protein response and inflammation in neuroserpinopathy

    Journal of Neuropathology and Experimental Neurology, Vol. 75, Núm. 2, pp. 121-133

2015

  1. Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins

    Trends in Biochemical Sciences

2011

  1. Enhanced expression of the voltage-dependent anion channel 1 (VDAC1) in alzheimer's disease transgenic mice: An insight into the pathogenic effects of amyloid-β

    Journal of Alzheimer's Disease, Vol. 23, Núm. 2, pp. 195-206

  2. Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease

    Movement Disorders, Vol. 26, Núm. 10, pp. 1943-1947

2010

  1. Calcium-mediated modulation of the quaternary structure and function of adenosine A2A-dopamine D2 receptor heteromers

    Current Opinion in Pharmacology, Vol. 10, Núm. 1, pp. 67-72